# Biotech Daily Digest ‚Äî 2025-12-18

**39 items from 5 sources**

## Summary by Source

- Eli Lilly Press Releases: 1 item
- Endpoints News: 11 items
- Fierce Biotech: 11 items
- MHRA ‚Äì News: 2 items
- arXiv q-bio: 14 items


## Eli Lilly Press Releases

- **[Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial](https://investor.lilly.com/news-releases/news-release-details/lillys-orforglipron-helped-people-maintain-weight-loss-after)**  
  _Thu, 18 Dec 2025 06:45:00 -0500_  
  In ATTAIN-MAINTAIN, orforglipron achieved the primary and all key secondary endpoints for weight maintenance vs. placebo at 52 weeks following weight loss on Wegovy or Zepbound Participants who switched to orforglipron from Wegovy maintained all but 0.9 kg of their previously achieved weight loss


## Endpoints News

- **[Insilico advances Hong Kong IPO, eyes $260M raise with Lilly's support](https://endpoints.news/insilico-advances-hong-kong-ipo-eyes-260m-raise-with-lillys-support/)**  
  _Thu, 18 Dec 2025 13:44:37 +0000_  
  Insilico Medicine is steps away from an initial public offering on the Hong Kong Stock Exchange after stalling on a few prior attempts.

 Insilico is seeking to raise net proceeds of approximately ...

- **[Moderna lands CEPI as new backer for its pandemic flu program](https://endpoints.news/moderna-lands-cepi-as-new-backer-for-its-pandemic-flu-program/)**  
  _Thu, 18 Dec 2025 12:00:43 +0000_  
  Moderna has snagged a new partner to help pay for a Phase 3 study of its H5 pandemic influenza vaccine, more than six months after the US axed funding for the project.

 The Coalition for ...

- **[GSK turns to Camp4 for neuro and kidney medicines](https://endpoints.news/gsk-turns-to-camp4-for-neuro-and-kidney-medicines/)**  
  _Thu, 18 Dec 2025 12:00:26 +0000_  
  GSK will enlist regulatory RNA biotech Camp4 Therapeutics to help find and create new neurodegenerative and kidney disease medicines.

 The deal is worth $17.5 million upfront, and as much as $440 million in development and ...

- **[Lilly‚Äôs orforglipron is the first oral obesity therapy to show its worth in the maintenance setting](https://endpoints.news/lillys-orforglipron-is-the-first-oral-obesity-therapy-to-show-its-worth-in-the-maintenance-setting/)**  
  _Thu, 18 Dec 2025 11:45:13 +0000_  
  Eli Lilly‚Äôs experimental obesity pill allowed patients who had lost weight on injected GLP-1-based drugs to keep most of the weight off for another year, according to data from a Phase 3 trial

- **[Empower Pharmacy cuts hundreds of staff, stops New Jersey operations](https://endpoints.news/empower-pharmacy-cut-hundreds-of-staff-stopped-new-jersey-operations/)**  
  _Wed, 17 Dec 2025 23:10:29 +0000_  
  Empower Pharmacy, a large GLP-1 compounding pharmacy that‚Äôs faced allegations of poor quality drugs and a legal challenge from Eli Lilly, has stopped operations at its New Jersey manufacturing facility and laid off hundreds of ...

- **[European Commission unveils EU Biotech Act as it lags behind other countries](https://endpoints.news/european-commission-unveils-eu-biotech-act-as-it-lags-behind-other-countries/)**  
  _Wed, 17 Dec 2025 18:45:32 +0000_  
  The European Commission has unveiled a long-awaited proposal to make Europe a "biotech powerhouse‚Äù by speeding up clinical trials, extending intellectual property protection and boosting biomanufacturing.

 The commission published the first half of the  ...

- **[CDC stops recommending universal hepatitis B birthdose](https://endpoints.news/cdc-stops-recommending-universal-hepatitis-b-birthdose/)**  
  _Wed, 17 Dec 2025 17:19:16 +0000_  
  The CDC adopted new hepatitis B vaccine recommendations, eliminating the universal birth dose guidance that had been on the books for decades.

 The agency now recommends that pregnant women who test ...

- **[GSK formally submits new leucovorin indication to FDA](https://endpoints.news/gsk-formally-submits-new-leucovorin-indication-to-fda/)**  
  _Wed, 17 Dec 2025 16:20:50 +0000_  
  GSK has submitted a new label to the FDA for its drug leucovorin, telling regulators that it can treat a developmental disorder that's been linked to autism.

 A company spokesperson confirmed the submission to  ...

- **[Padcev-Keytruda combination notches another bladder cancer win](https://endpoints.news/padcev-keytruda-combination-notches-another-bladder-cancer-win/)**  
  _Wed, 17 Dec 2025 16:07:05 +0000_  
  Pfizer, Astellas and Merck announced Wednesday that the combination of Padcev and Keytruda helped certain bladder cancer patients live longer in a Phase 3 trial, and plan to take the regimen to regulators to discuss ...

- **[RTW's Yarrow to go public in reverse merger with Vyne Therapeutics](https://endpoints.news/rtws-yarrow-to-go-public-in-reverse-merger-with-vyne-therapeutics/)**  
  _Wed, 17 Dec 2025 15:47:20 +0000_  
  Vyne Therapeutics will hand its Nasdaq spot to RTW's Yarrow Bioscience in a reverse merger that will also bring a $200 million cash infusion into the biotech.

 The all-stock transaction

- **[Vir licensing deal; Cytokinetics wins China nod; Vistagen's social anxiety fail](https://endpoints.news/vir-licensing-deal-cytokinetics-wins-china-nod-vistagens-social-anxiety-fail/)**  
  _Wed, 17 Dec 2025 15:00:12 +0000_  
  Plus, news about Neurocrine, TargED, T-CURX, Immunome and Kodiak:

 ü§ù Vir Biotechnology's licensing deal: An affiliate of Norgine Pharma will take the commercial rights to the experimental chronic hepatitis delta combo


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/lillys-obesity-pill-largely-maintains-weight-lost-injectable-glp-1s-putting-novos-wegovy" hreflang="en">Lilly's obesity pill largely maintains weight lost on injectable GLP-1s</a>](https://www.fiercebiotech.com/biotech/lillys-obesity-pill-largely-maintains-weight-lost-injectable-glp-1s-putting-novos-wegovy)**  
  _Dec 18, 2025 7:59am_  
  Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug candidate, teeing the drugmaker up to target people taking Novo Nordisk‚Äôs Wegovy.

- **[<a href="https://www.fiercebiotech.com/biotech/takeda-looks-2026-fda-filing-its-sotyktu-rival-zasocitinib-after-phase-3-success" hreflang="en">Takeda looks to 2026 FDA filing for its Sotyktu rival zasocitinib after phase 3 success </a>](https://www.fiercebiotech.com/biotech/takeda-looks-2026-fda-filing-its-sotyktu-rival-zasocitinib-after-phase-3-success)**  
  _Dec 18, 2025 3:42am_  
  Takeda‚Äôs closely watched and highly valued dermatology pill zasocitinib has won out in two key phase 3 trials as the Japanese pharma looks to file the drug in the U.S. next year.

- **[<a href="https://www.fiercebiotech.com/biotech/gsk-pays-175m-pitch-its-tent-camp4-regulatory-rna-deal" hreflang="en">GSK pays $17.5M for CAMP4 regulatory RNA deal </a>](https://www.fiercebiotech.com/biotech/gsk-pays-175m-pitch-its-tent-camp4-regulatory-rna-deal)**  
  _Dec 18, 2025 4:18am_  
  GSK is embarking on a journey with CAMP4 Therapeutics, paying $17.5 million upfront to collaborate on regulatory RNA-targeting therapeutics in neurodegenerative and kidney disease indications.

- **[<a href="https://www.fiercebiotech.com/biotech/voyager-jettisons-30-employees-novartis-hands-back-rights-2-programs" hreflang="en">Voyager jettisons 30 employees, Novartis hands back rights to 2 programs</a>](https://www.fiercebiotech.com/biotech/voyager-jettisons-30-employees-novartis-hands-back-rights-2-programs)**  
  _Dec 17, 2025 4:34pm_  
  Neurology biotech Voyager Therapeutics has laid off 30 employees, a spokesperson for the Massachusetts-based company confirmed to Fierce Biotech.

- **[<a href="https://www.fiercebiotech.com/biotech/vistagens-ph3-flop-puts-future-fasedienol-social-anxiety-question-william-blair" hreflang="en">Vistagen phase 3 study sees placebo surprise, putting future of social anxiety asset into question: analyst</a>](https://www.fiercebiotech.com/biotech/vistagens-ph3-flop-puts-future-fasedienol-social-anxiety-question-william-blair)**  
  _Dec 17, 2025 2:18pm_  
  After a late-stage miss for Vistagen's prospective social anxiety disorder treatment fasedienol, the company's chances at an FDA approval in the indication are looking slimmer.

- **[<a href="https://www.fiercebiotech.com/cro/lindus-health-and-quotient-team-create-one-stop-shop-early-midstage-trials" hreflang="en">Lindus Health and Quotient team up to create one-stop shop for early to mid-stage trials</a>](https://www.fiercebiotech.com/cro/lindus-health-and-quotient-team-create-one-stop-shop-early-midstage-trials)**  
  _Dec 17, 2025 2:36pm_  
  Clinical development accelerator Quotient Sciences and CRO Lindus Health are joining forces to create a streamlined process for clients to advance from first-in-human (FIH) to pivotal trials.

- **[<a href="https://www.fiercebiotech.com/biotech/fired-nih-institute-director-sues-trump-health-officials-calling-ouster-illegal" hreflang="en">Fired NIH institute director sues Trump health officials, seeks reinstatement and backpay</a>](https://www.fiercebiotech.com/biotech/fired-nih-institute-director-sues-trump-health-officials-calling-ouster-illegal)**  
  _Dec 17, 2025 12:29pm_  
  The former director of the National Institutes of Health‚Äôs National Institute of Allergy and Infectious Diseases is suing Trump administration officials over her September firing, which she alleges violated her rights and was illegal under federal whistleblower protections.

- **[<a href="https://www.fiercebiotech.com/biotech/norgine-gets-virs-hepatitis-d-program-eu550-european-licensing-pact" hreflang="en">Norgine gets in on Vir's hepatitis D program with ‚Ç¨550 European licensing pact</a>](https://www.fiercebiotech.com/biotech/norgine-gets-virs-hepatitis-d-program-eu550-european-licensing-pact)**  
  _Dec 17, 2025 11:18am_  
  Norgine secured an exclusive license to commercialize Vir Biotechnology's combo hepatitis D prospect of tobevibart and elebsiran in Europe, Australia and New Zealand.

- **[<a href="https://www.fiercebiotech.com/biotech/oncology-biotech-mythic-and-former-fundraising-heavy-weight-areteia-wind-down" hreflang="en">Oncology biotech Mythic and former fundraising heavyweight Areteia reach end of road</a>](https://www.fiercebiotech.com/biotech/oncology-biotech-mythic-and-former-fundraising-heavy-weight-areteia-wind-down)**  
  _Dec 17, 2025 11:12am_  
  After layoffs this fall, Mythic Therapeutics is winding down, while asthma-focused Areteia Therapeutics is reportedly shuttering mere months after reporting a phase 3 win for its oral biologic.

- **[<a href="https://www.fiercebiotech.com/medtech/medline-makes-nasdaq-debut-raising-626b-years-largest-ipo" hreflang="en">Medline makes Nasdaq debut, raising $6.26B in year's largest IPO</a>](https://www.fiercebiotech.com/medtech/medline-makes-nasdaq-debut-raising-626b-years-largest-ipo)**  
  _Dec 17, 2025 10:41am_  
  After operating outside the spotlight for years, Medline is taking center stage with the biggest IPO of the year.

- **[<a href="https://www.fiercebiotech.com/medtech/medtronics-thrombectomy-system-goes-live-embolization-system-adds-indication" hreflang="en">Medtronic rolls out new peripheral thrombectomy system while making advances in brain bleeds</a>](https://www.fiercebiotech.com/medtech/medtronics-thrombectomy-system-goes-live-embolization-system-adds-indication)**  
  _Dec 17, 2025 8:42am_  
  The Liberant aspiration catheters are designed to snake into blocked arteries and veins in the arms and legs, while Medtronic's Onyx liquid embolic system gained a new use in subdural hematoma.


## MHRA ‚Äì News

- **[MHRA seeks input on AI regulation at ‚Äòpivotal moment‚Äô for healthcare](https://www.gov.uk/government/news/mhra-seeks-input-on-ai-regulation-at-pivotal-moment-for-healthcare)**  
  _2025-12-18T09:30:12Z_  
  National Commission is seeking evidence to shape regulation of AI in healthcare and support the UK‚Äôs ambition for a world-leading, AI-enabled NHS

- **[Regulation of AI in Healthcare](https://www.gov.uk/government/calls-for-evidence/regulation-of-ai-in-healthcare)**  
  _2025-12-18T00:00:00Z_  
  The MHRA is seeking evidence on the regulation of AI in healthcare to inform the recommendations of the National Commission into the Regulation of AI in Healthcare.


## arXiv q-bio

- **[The Role of Affect and Priors in the Generation of Hallucinations in Early Psychosis](https://arxiv.org/abs/2512.14743)**  
  _Thu, 18 Dec 2025 00:00:00 -0500_  
  arXiv:2512.14743v1 Announce Type: new 
Abstract: Background: Stress and negative affect play significant roles in developing psychosis. Bayesian analyses applied to the conditioned hallucinations (CH) task suggest that hallucinations arise when maladaptive prior beliefs outweigh sensory evidence. Prior weighting is li‚Ä¶

- **[Multiscale Cross-Modal Mapping of Molecular, Pathologic, and Radiologic Phenotypes in Lipid-Deficient Clear Cell Renal CellCarcinoma](https://arxiv.org/abs/2512.14750)**  
  _Thu, 18 Dec 2025 00:00:00 -0500_  
  arXiv:2512.14750v1 Announce Type: new 
Abstract: Clear cell renal cell carcinoma (ccRCC) exhibits extensive intratumoral heterogeneity on multiple biological scales, contributing to variable clinical outcomes and limiting the effectiveness of conventional TNM staging, which highlights the urgent need for multiscale in‚Ä¶

- **[Characterizing Open-Ended Evolution Through Undecidability Mechanisms in Random Boolean Networks](https://arxiv.org/abs/2512.15534)**  
  _Thu, 18 Dec 2025 00:00:00 -0500_  
  arXiv:2512.15534v1 Announce Type: new 
Abstract: Discrete dynamical models underpin systems biology, but we still lack substrate-agnostic diagnostics for when such models can sustain genuinely open-ended evolution (OEE): the continual production of novel phenotypes rather than eventual settling. We introduce a simple,‚Ä¶

- **[Machine learning for RNA-targeting drug design](https://arxiv.org/abs/2512.15645)**  
  _Thu, 18 Dec 2025 00:00:00 -0500_  
  arXiv:2512.15645v1 Announce Type: new 
Abstract: Targeting RNA with small molecules offers significant therapeutic potential.
  Machine learning could substantially accelerate preclinical drug discovery, from hit identification to lead optimization.
  Yet a fundamental limitation emerges: drug design machine learning‚Ä¶

- **[When sufficiency is insufficient: the functional information bottleneck for identifying probabilistic neural representations](https://arxiv.org/abs/2512.15671)**  
  _Thu, 18 Dec 2025 00:00:00 -0500_  
  arXiv:2512.15671v1 Announce Type: new 
Abstract: The neural basis of probabilistic computations remains elusive, even amidst growing evidence that humans and other animals track their uncertainty. Recent work has proposed that probabilistic representations arise naturally in task-optimized neural networks trained with‚Ä¶

- **[A multiscale framework integrating within-host infection kinetics with airborne transmission dynamics](https://arxiv.org/abs/2512.15209)**  
  _Thu, 18 Dec 2025 00:00:00 -0500_  
  arXiv:2512.15209v1 Announce Type: cross 
Abstract: Coupling within-host infection dynamics with population-level transmission remains a major challenge in infectious disease modeling, especially for airborne pathogens with potential to spread indoor. The frequent emergence of such diseases highlight the need for integ‚Ä¶

- **[Modeling Plant Action Potentials under Photoperiod Stress via Hodgkin-Huxley Dynamics](https://arxiv.org/abs/2512.15236)**  
  _Thu, 18 Dec 2025 00:00:00 -0500_  
  arXiv:2512.15236v1 Announce Type: cross 
Abstract: Plants exhibit dynamic bioelectric properties that facilitate information transfer across tissues. This study investigates action potentials (APs) in Nicotiana tabacum recorded within a custom-designed growth chamber using a biosignal amplifier and environmental senso‚Ä¶

- **[Learning Model Parameter Dynamics in a Combination Therapy for Bladder Cancer from Sparse Biological Data](https://arxiv.org/abs/2512.15706)**  
  _Thu, 18 Dec 2025 00:00:00 -0500_  
  arXiv:2512.15706v1 Announce Type: cross 
Abstract: In a mathematical model of interacting biological organisms, where external interventions may alter behavior over time, traditional models that assume fixed parameters usually do not capture the evolving dynamics. In oncology, this is further exacerbated by the fact t‚Ä¶

- **[Primer C-VAE: An interpretable deep learning primer design method to detect emerging virus variants](https://arxiv.org/abs/2503.01459)**  
  _Thu, 18 Dec 2025 00:00:00 -0500_  
  arXiv:2503.01459v2 Announce Type: replace 
Abstract: Motivation: PCR is more economical and quicker than Next Generation Sequencing for detecting target organisms, with primer design being a critical step. In epidemiology with rapidly mutating viruses, designing effective primers is challenging. Traditional methods re‚Ä¶

- **[FAIR sharing of Chromatin Tracing datasets using the newly developed 4DN FISH Omics Format](https://arxiv.org/abs/2508.13255)**  
  _Thu, 18 Dec 2025 00:00:00 -0500_  
  arXiv:2508.13255v3 Announce Type: replace 
Abstract: In recent years, multiplexed Fluorescence In Situ Hybridization (FISH) or FISH-omics methods have rapidly expanded, enabling the quantification of chromatin organization in single cells, often in conjunction with measurements of RNA and protein. These approaches hav‚Ä¶

- **[A tutorial on electrogastrography using low-cost hardware and open-source software](https://arxiv.org/abs/2509.17260)**  
  _Thu, 18 Dec 2025 00:00:00 -0500_  
  arXiv:2509.17260v2 Announce Type: replace 
Abstract: Electrogastrography is the recording of changes in electric potential caused by the stomach's pacemaker region, typically through several cutaneous sensors placed on the abdomen. It is a worthwhile technique in medical and psychological research, but also relatively‚Ä¶

- **[Reducing Recurrent Competitive Epidemics via Dynamic Resource Allocation](https://arxiv.org/abs/2006.13395)**  
  _Thu, 18 Dec 2025 00:00:00 -0500_  
  arXiv:2006.13395v2 Announce Type: replace-cross 
Abstract: Motivated by scenarios of epidemic competition, as well as how social contagions spread at the level of individuals, this work considers the competition between two conflicting node states that spread over a social graph according to a generic diffusion proces‚Ä¶

- **[Sufficient condition for dispersal-induced growth on dynamic networks](https://arxiv.org/abs/2411.07821)**  
  _Thu, 18 Dec 2025 00:00:00 -0500_  
  arXiv:2411.07821v2 Announce Type: replace-cross 
Abstract: We consider a population spreading across a finite number of sites. Individuals can move from one site to the other according to a network (oriented links between the sites) that vary periodically over time. On each site, the population experiences a growth ra‚Ä¶

- **[Dynamical stability for dense patterns in discrete attractor neural networks](https://arxiv.org/abs/2507.10383)**  
  _Thu, 18 Dec 2025 00:00:00 -0500_  
  arXiv:2507.10383v3 Announce Type: replace-cross 
Abstract: Neural networks storing multiple discrete attractors are canonical models of biological memory. Previously, the dynamical stability of such networks could only be guaranteed under highly restrictive conditions. Here, we derive a theory of the local stability o‚Ä¶
